Business Context and Reporting Period
This Form 8-K, filed on July 17, 2020, reports on events occurring on July 17, 2020, and closing on July 21, 2020, for Hancock Jaffe Laboratories, Inc. (HJLI). The filing details a firm commitment public offering and a concurrent private placement designed to raise capital and regain compliance with Nasdaq listing requirements regarding minimum stockholders' equity.
Key Financial Metrics and Capitalization
- Net Proceeds: Approximately $5.2 million from the combined Public Offering and Private Placement, after underwriting discounts and estimated expenses.
- Cash Position: Increased from $720,131 (actual as of March 31, 2020) to an adjusted $4,453,131 following the transactions.
- Stockholders' Equity: Improved from a deficiency of $(14,623) to $5,171,557 on an as-adjusted basis.
- Public Offering Structure: Sale of 14,375,000 Units (including full exercise of the overallotment option) at $0.32 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase one share.
- Private Placement Structure: Sale of 4,205,406 shares of Series C Convertible Preferred Stock at $0.37 per share and unregistered warrants to purchase up to 6,078,125 shares of Common Stock.
- Outstanding Shares: Post-transaction Common Stock outstanding is 38,324,333 shares (excluding warrant exercises).
Material Changes Versus Prior Period
The most significant change is the elimination of the stockholders' equity deficiency. As of March 31, 2020, the company reported a total capitalization deficiency of $(14,623). The capital raise has adjusted this to a positive equity position of $5,171,557. Additionally, the company has issued new equity instruments, including Series C Convertible Preferred Stock and a substantial number of warrants, which were not present in the prior period's capital structure.
Outlook, Management Commentary, and Risks
- Nasdaq Compliance: Management states the transactions enable the company to regain compliance with the Nasdaq Capital Market minimum $2.5 million stockholders' equity threshold. The company is awaiting formal confirmation from Nasdaq.
- Lock-Up Agreements: Officers, directors, and certain investors are subject to 90-day lock-up periods restricting the sale of securities. Certain investors also agreed to vote their shares on specific proposals.
- Preferred Stock Terms: The Series C Preferred Stock accrues dividends in kind at an annual rate of 8.0% of the purchase price. It ranks senior to Common Stock and includes automatic conversion triggers if the company consummates a merger or raises at least $8 million in gross proceeds within 12 months following a "Capital Event."
- Warrant Exercisability: Both Public and Private Warrants are exercisable only after stockholder approval of an increase in authorized shares or a reverse stock split sufficient to permit full exercise.
Investor Verification Checklist
- Confirm receipt of Nasdaq's formal determination regarding the company's compliance with listing standards.
- Verify the final closing date and actual net proceeds received, as the $5.2 million figure is an estimate.
- Monitor the timeline for the stockholder meeting required to approve the increase in authorized shares, which is a condition precedent for warrant exercisability and preferred stock conversion.
- Review the specific terms of the Series C Preferred Stock dividend accruals and their impact on future cash flow or dilution.
- Check for any subsequent filings regarding the registration rights agreement for the resale of Private Warrant Shares.